IDÀúÀå 
ùȭ¸éÀ¸·Î
°øÁö»çÇ×
°Ô½ÃÆÇ
ÄûÁîÄûÁî
ÁÖÀÓ±³¼ö Àλ縻
µ¿¹®È¸Àå Àλ縻
±³½Ç¿ª»ç
¿ª´ë ÁÖÀÓ±³¼ö
¿ª´ë µ¿¹®È¸Àå
±³½Ç¿ø ¼Ò°³
Àü°øÀÇ ¼Ò°³
ÀÚÁÖ ¿¬¶ôÇսôÙ
°ø½ÄÇà»ç
¿ì¸®´Â Çϳª
Ãß¾ïÀÇ ¾Ù¹ü
News Letter
¿¬º¸
¼ö¿ä Conference
¿©Àǵµ¼º¸ð
°­³²¼º¸ð
ÀÇÁ¤ºÎ¼º¸ð
¼ººó¼¾Æ®
¼º¸ðÀÚ¾Ö
¼º°¡
¼º¹Ù¿À·Î
´ëÀü¼º¸ð
°¡Å縯½ÉÆ÷Áö¿ò
µ¿¹®Çмú´ëȸ
º¸¹°Ã¢°í
µðīŬ·´
Á¤º¸¼öÁ¤
ÀÔÅð¿ø¼ö¼ú °ü¸®

 
ÀÛ¼ºÀÚ ºñ´¢±â°úÇб³½Ç µî·ÏÀÏ 2010-10-18 12:49:36
Á¶È¸ 740 ´Ù¿î 0
Á¦¸ñ   10¿ù20ÀÏ ¼ö¿äÃʵ¶È¸ °øÁö
÷ºÎÆÄÀÏ    
³»¿ë
ÁÖÁ¦ : Management of non-muscle invasive bladder cancer

ÁÂÀå : ÇÏÀ¯½Å ±³¼ö

¹ßÇ¥ÀÚ :
R2 ±è ¼³ :
Radical cystectomy for TaT1 bladder cancer

R3. °­¼¼Èñ :
adjuvant intravesical treatment : optimal schedule & dose


Ref) EAU 2010
- Guidelines on TaT1 (Non-muscle invasive) Bladder cancer
- Recurrence and Progression of Disease in Non-Muscle-Invasive Bladder cancer :
From Epidemiology to Treatment Strategy



ÀϽà : 2010³â 10¿ù 20ÀÏ (¼ö) ¿ÀÈÄ 6½Ã 00ºÐ
Àå¼Ò : º»°ü 4Ãþ °­´ç

ÀÌÀü±Û   °áÈ¥¼Ò½Ä ÀüÇÕ´Ï´Ù. - ¾ÈÁ¾ÈÆ µ¿¹® Â÷³à °áÈ¥
ÀÌÈÄ±Û   °í³âÂ÷ Àü°øÀǸ¦ À§ÇÑ staff lecture

 
¸®Çôޱâ